COLL at an All-Time HighCompany has given very positive Guidance. Great volume today. Not the best candle, but might have been better if the market showed better strength. High short float might get this moving with a squeeze!
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
2.74 USD
48.16 M USD
566.77 M USD
31.12 M
About Collegium Pharmaceutical, Inc.
Sector
CEO
Vikram Karnani
Headquarters
Stoughton
Website
Founded
2002
FIGI
BBG000N7LPW4
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
Collegium Announces $100 Million Share Repurchase Program!!!COLL: Collegium Pharmaceutical, Inc.
2021-08-16 08:00:00
Collegium Announces $100 Million Share Repurchase Program
COLL Long - 4/2/2019COLL is in a week downtrend currently; however strong line of resistance has been drawn. Bet on rebound on resistance to slightly higher level of support. Quick conservative trade.
Trade responsibly; TPs and SLs
Long on COLLBullish Pinbar on weekly chart
Long term trend line support
Near term horizontal support
Confirmed bounce started (weekly candle closed green)
Bearish CrabCOLL, No Position, lets see if it works its way down to the levels below it, still learning. Time frame is 1st of March.
Upper trendline retestedWe are moving down since April 7th. As we are close to the cloud we may assume that the break above the sshort channel may be difficult.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
COLL5756983
Collegium Pharmaceutical, Inc. 2.875% 15-FEB-2029Yield to maturity
0.88%
Maturity date
Feb 15, 2029
Explore more bonds
Frequently Asked Questions
The current price of COLL is 29.06 USD — it has decreased by −0.31% in the past 24 hours. Watch Collegium Pharmaceutical, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Collegium Pharmaceutical, Inc. stocks are traded under the ticker COLL.
COLL stock has fallen by −5.22% compared to the previous week, the month change is a −4.41% fall, over the last year Collegium Pharmaceutical, Inc. has showed a −5.13% decrease.
We've gathered analysts' opinions on Collegium Pharmaceutical, Inc. future price: according to them, COLL price has a max estimate of 50.00 USD and a min estimate of 37.00 USD. Watch COLL chart and read a more detailed Collegium Pharmaceutical, Inc. stock forecast: see what analysts think of Collegium Pharmaceutical, Inc. and suggest that you do with its stocks.
COLL reached its all-time high on Oct 7, 2024 with the price of 42.29 USD, and its all-time low was 7.37 USD and was reached on May 9, 2017. View more price dynamics on COLL chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
COLL stock is 1.77% volatile and has beta coefficient of 0.30. Track Collegium Pharmaceutical, Inc. stock price on the chart and check out the list of the most volatile stocks — is Collegium Pharmaceutical, Inc. there?
Today Collegium Pharmaceutical, Inc. has the market capitalization of 937.19 M, it has decreased by −5.66% over the last week.
Yes, you can track Collegium Pharmaceutical, Inc. financials in yearly and quarterly reports right on TradingView.
Collegium Pharmaceutical, Inc. is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
COLL earnings for the last quarter are 1.61 USD per share, whereas the estimation was 1.59 USD resulting in a 1.16% surprise. The estimated earnings for the next quarter are 1.50 USD per share. See more details about Collegium Pharmaceutical, Inc. earnings.
Collegium Pharmaceutical, Inc. revenue for the last quarter amounts to 159.30 M USD, despite the estimated figure of 155.65 M USD. In the next quarter, revenue is expected to reach 179.48 M USD.
COLL net income for the last quarter is 9.34 M USD, while the quarter before that showed 19.61 M USD of net income which accounts for −52.39% change. Track more Collegium Pharmaceutical, Inc. financial stats to get the full picture.
No, COLL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 197.00 employees. See our rating of the largest employees — is Collegium Pharmaceutical, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Collegium Pharmaceutical, Inc. EBITDA is 361.47 M USD, and current EBITDA margin is 57.29%. See more stats in Collegium Pharmaceutical, Inc. financial statements.
Like other stocks, COLL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Collegium Pharmaceutical, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Collegium Pharmaceutical, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Collegium Pharmaceutical, Inc. stock shows the neutral signal. See more of Collegium Pharmaceutical, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.